Chewable Tablet Adverse Events, Manufacturing Slips Prompt Guidance
This article was originally published in The Gold Sheet
Executive Summary
Chewable tablet manufacturers are overlooking quality attributes, leading to adverse events, according to an FDA draft guidance document. The agency recommends firms establish hardness, dissolution and disintegration of products early in manufacturing.
You may also be interested in...
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
Final FDA Guidance Delivers More Digestible Tablet Chewing Index
FDA’s final guidance on chewable tablets clarifies what is meant by a “chewing difficulty index” to assess product hardness. Properly formulating these products is key to avoiding quality failures such as choking patients.
Scrip M&A Podcast: Which Companies Could Be Acquired Next?
The editorial team from Scrip discusses the M&A potential of various emerging biopharmas, such as Viking, Verona, Altimmune, Xenon and Crinetics.